| Print
Theravance Biopharma (TBPH)
Ordinary SharesNot yet a customer?
Low cost dealing from £1.50Choose from our range of SIPP, ISA and Dealing accounts
Find out moreThis share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP
Company profile
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
Address
Ugland House, South Church Street
George Town, PO Box 309
Grand Cayman
CYM
KY1-1104
Telephone
+1 650 8084045
Forecast key dates
| Name | Key Date |
|---|---|
| Theravance Biopharma Inc Second Quarter Earnings Conference Call for 2026 | 2026-08-12T17:00:00 |
| Theravance Biopharma Inc Second Quarter Earnings Results for 2026 | 2026-08-12T00:00:00 |
| Theravance Biopharma Inc Annual General Meeting for 2026 | 2026-05-19T17:00:00 |
| Theravance Biopharma Inc First Quarter Earnings Conference Call for 2026 | 2026-05-08T17:00:00 |
| Theravance Biopharma Inc First Quarter Earnings Results for 2026 | 2026-05-08T00:00:00 |
| Theravance Biopharma Inc Annual Report for 2025 | 2026-03-06T00:00:00 |
| Theravance Biopharma Inc Fourth Quarter Earnings Conference Call for 2025 | 2026-02-26T17:00:00 |
| Theravance Biopharma Inc Fourth Quarter Earnings Results for 2025 | 2026-02-26T00:00:00 |
| Theravance Biopharma Inc Third Quarter Earnings Conference Call for 2025 | 2025-11-12T17:00:00 |
| Theravance Biopharma Inc Third Quarter Earnings Results for 2025 | 2025-11-12T00:00:00 |
Previous key dates
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2025 AJ Bell. All rights reserved.